178 related articles for article (PubMed ID: 35912092)
1. Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma.
Vergani E; Beretta GL; Aloisi M; Costantino M; Corno C; Frigerio S; Tinelli S; Dugo M; Accattatis FM; Granata A; Arnaboldi L; Rodolfo M; Perego P; Gatti L
Front Cell Dev Biol; 2022; 10():927118. PubMed ID: 35912092
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
3. Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming.
Chang MT; Tsai LC; Nakagawa-Goto K; Lee KH; Shyur LF
Pharmacol Res; 2022 Apr; 178():106148. PubMed ID: 35231572
[TBL] [Abstract][Full Text] [Related]
4. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
[TBL] [Abstract][Full Text] [Related]
5. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
6. Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations.
Stamatakos S; Beretta GL; Vergani E; Dugo M; Corno C; Corna E; Tinelli S; Frigerio S; Ciusani E; Rodolfo M; Perego P; Gatti L
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34068792
[TBL] [Abstract][Full Text] [Related]
7. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
9. PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism.
Garbarino O; Valenti GE; Monteleone L; Pietra G; Mingari MC; Benzi A; Bruzzone S; Ravera S; Leardi R; Farinini E; Vernazza S; Grottoli M; Marengo B; Domenicotti C
Front Oncol; 2023; 13():1210130. PubMed ID: 37534247
[TBL] [Abstract][Full Text] [Related]
10. Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines.
Bemlih S; Poirier MD; El Andaloussi A
Cancer Biol Ther; 2010 Jun; 9(12):1025-32. PubMed ID: 20404512
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
12. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
13. Cell surface CD63 increased by up-regulated polylactosamine modification sensitizes human melanoma cells to the BRAF inhibitor PLX4032.
Kudo K; Yoneda A; Sakiyama D; Kojima K; Miyaji T; Yamazaki M; Yaita S; Hyodo T; Satow R; Fukami K
FASEB J; 2019 Mar; 33(3):3851-3869. PubMed ID: 30508500
[TBL] [Abstract][Full Text] [Related]
14. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
Delgado-Goñi T; Galobart TC; Wantuch S; Normantaite D; Leach MO; Whittaker SR; Beloueche-Babari M
Br J Cancer; 2020 Jan; 122(1):72-81. PubMed ID: 31819183
[TBL] [Abstract][Full Text] [Related]
15. Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway.
Li Z; Liu X; Li M; Chai J; He S; Wu J; Xu J
Mol Med Rep; 2020 Jul; 22(1):566-574. PubMed ID: 32377702
[TBL] [Abstract][Full Text] [Related]
16. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
Madorsky Rowdo FP; Barón A; Gallagher SJ; Hersey P; Emran AA; Von Euw EM; Barrio MM; Mordoh J
Int J Oncol; 2020 Jun; 56(6):1429-1441. PubMed ID: 32236593
[TBL] [Abstract][Full Text] [Related]
18. Chk1 inhibition as a novel therapeutic strategy in melanoma.
Hwang BJ; Adhikary G; Eckert RL; Lu AL
Oncotarget; 2018 Jul; 9(54):30450-30464. PubMed ID: 30100999
[TBL] [Abstract][Full Text] [Related]
19. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
Martin S; Dudek-Perić AM; Maes H; Garg AD; Gabrysiak M; Demirsoy S; Swinnen JV; Agostinis P
Biochem Pharmacol; 2015 Feb; 93(3):290-304. PubMed ID: 25529535
[TBL] [Abstract][Full Text] [Related]
20. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
